Accessibility Menu
Nexalin Technology logo

Nexalin Technology(NASDAQ) NXLIW

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-95%
5 YearN/A
1 Year-87%
1 Month-44%
$0.00
+0.00%
+0.00Today
Nexalin Technology last closing stock price
MetricPriceDate
Last closeUSD 0.012025-09-19
Nexalin Technology stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-13.21%USD 0.022025-09-12
1 month-44.13%USD 0.022025-08-20
3 month-82.75%USD 0.082025-06-20
Year to date-96.06%USD 0.352024-12-31
1 year-86.53%USD 0.102024-09-19
3 year-93.43%USD 0.212022-09-20
Since inception-94.58%USD 0.252022-09-16

Nexalin Technology Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$217.16K

Net Income (TTM)

-$8.99M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

$0.00

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 6, 2025

NXLIW News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nexalin Technology

Nexalin Technology, Inc. is a Houston-based medical device company focused on developing innovative neurostimulation solutions for mental health conditions. Founded in 2021, the company aims to provide non-invasive, drug-free therapeutic options, primarily through its flagship product, the Nexalin Device.

Products and Services
  • Nexalin Device: A non-invasive device for managing anxiety and insomnia
  • Generation 2 Device: In development for treating opiate-related substance abuse and chronic pain
  • Clinical trials ongoing for Alzheimer's disease and dementia treatments
Growth Outlook
  • Market potential in the U.S. and China for mental health solutions is significant
  • Ongoing clinical trials may expand product offerings and market reach
  • Focus on innovative technology positions Nexalin for future growth
Financial Highlights
  • Q2 2026 revenue of $12,161, showing a focus on product adoption
  • Operating expenses for Q2 2026 reached $2,256,212, indicating investment in growth
  • Cash and cash equivalents of $1,004,958 as of June 30, 2026, providing liquidity
Nexalin Technology, Inc. is positioned in the healthcare sector, specifically within the medical devices industry. The company's innovative approach to neurostimulation addresses a growing need for effective mental health treatments. The Nexalin Device's unique technology aims to provide relief for conditions such as anxiety and insomnia, which are prevalent in today's society. The growth outlook for Nexalin is promising, with significant market potential in both the United States and China. The ongoing development of the Generation 2 Device, which targets additional serious conditions, could further enhance the company's product portfolio and market presence. Financially, while the company is currently operating at a loss, the recent revenue figures and cash reserves indicate a commitment to investing in future growth. The focus on research and development, alongside clinical trials, suggests that Nexalin is actively working to establish itself as a leader in the neurostimulation market. Overall, Nexalin Technology, Inc. presents an intriguing opportunity for investors interested in the healthcare and medical device sectors, particularly in innovative solutions for mental health challenges.
AI Generated • Aug 21, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Headquarters

Houston, TX 77056, US

NXLIW Financials

Key Financial Metrics (TTM)

Gross Margin

-148.42%

Operating Margin

-4202.54%

Net Income Margin

-4139.38%

Return on Equity

-278.25%

Return on Capital

-223.88%

Return on Assets

-299.21%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$322.31K

Operating Income

-$9.13M

EBITDA

-$8.97M

Operating Cash Flow

-$6.13M

Capital Expenditure

-$82.91K

Free Cash Flow

-$6.21M

Cash & ST Invst.

$1.00M

Total Debt

$0.00

Nexalin Technology Performance Analysis

Nexalin Technology sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-74.3%
Q42025-12-31847.1%
Q12026-03-31-91.3%
Q22026-06-30-18.7%
Nexalin Technology sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-30.0%
Q42025-12-31N/A
Q12026-03-3115.4%
Q22026-06-300.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$12.16K

-82.8%

Gross Profit

$8.90K

-81.4%

Gross Margin

73.16%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

6

N/A

Net Income

-$2.24M

-41.6%

EBITDA

-$2.24M

-42.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.00M

-82.7%

Total Debt

$0.00

N/A

Accounts Receivable

$52.93K

-11.5%

Inventory

$233.46K

+35.0%

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-2.99%

N/A

Return on Invested Capital

-6.01%

N/A

Free Cash Flow

-$1.80M

-96.4%

Operating Cash Flow

-$1.80M

-96.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
QTIQT Imaging Holdings, Inc.
$2.93-5.18%
NURONeuroMetrix, Inc.
$4.58+5.05%
CYCCCyclacel Pharmaceuticals, Inc.
$6.37-5.98%
DOLEDole plc
$13.85+0.51%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About NXLIW

What is the current price of Nexalin Technology?

Nexalin Technology is trading at N/A per share.

What is the 52-week range for Nexalin Technology?

Over the past 52 weeks, Nexalin Technology has traded between N/A and N/A.

How much debt does Nexalin Technology have?

Nexalin Technology total debt is unavailable.

How much cash does Nexalin Technology have on hand?

Nexalin Technology does not have cash on hand data available.

What is Nexalin Technology’s dividend yield?

Nexalin Technology does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services